CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Pancreatic cancer (PC) is characterized by high chemoresistance and poor prognosis. CUL2, a scaffold protein of E3 ubiquitin ligases, has been implicated in tumor progression, but its role in PC remains unclear. METHODS: CUL2 expression was analyzed in PC tissues and cell lines using TCGA and GEO datasets, qRT-PCR, Western blot, and immunohistochemistry analysis. The biological functions of CUL2 were investigated through gain- and loss-of-function studies in vitro. The impact of CUL2 overexpression on gemcitabine sensitivity was evaluated in xenograft models. Molecular mechanisms were explored using proteasome inhibitor MG132, co-immunoprecipitation, subcellular fractionation, and ferroptosis assessment. RESULTS: CUL2 was significantly upregulated in PC tissues and correlated with poor prognosis. CUL2 promoted PC cell proliferation, migration, and EMT. Mechanistically, CUL2 competed with NRF2 for KEAP1 binding, thereby preventing KEAP1-mediated NRF2 degradation and promoting NRF2 nuclear translocation. CUL2 promoted oxidative stress while activating NRF2-dependent antioxidant response. The CUL2-NRF2 axis suppressed ferroptosis and conferred gemcitabine resistance in PC cells. In xenograft models, CUL2 overexpression enhanced tumor growth and attenuated gemcitabine sensitivity through NRF2-mediated ferroptosis inhibition. CONCLUSIONS: Our findings reveal a novel mechanism whereby CUL2 promotes PC progression and ferroptosis resistance through regulation of the KEAP1-NRF2 axis. CUL2 overexpression enhances cellular antioxidant capacity and maintains mitochondrial integrity, thereby conferring broad resistance to ferroptosis-inducing conditions. This study suggests that targeting the CUL2-NRF2 axis to enhance ferroptosis sensitivity might represent a promising therapeutic strategy for PC treatment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation
- Date Crossref
- 16/12/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shanghai University of Traditional Chinese Medicine Longhua Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Longhua Hospital Shanghai University of Traditional Chinese Medicine pays non établi dans la noticeÉtablissement de santé
-
Tongji University Department of Nuclear Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai Tenth People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Shanghai First People's Hospital pays non établi dans la noticeÉtablissement de santé
-
School of Medicine Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
Longhua Hospital — Shanghai University of Traditional Chinese Medicine, Longhua Hospital Shanghai University of Traditional Chinese Medicine et Department of Nuclear Medicine — Tongji University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.